Need Help?

Genomic analyses (WES, RNAseq, scRNAseq and scTCRseq) of triple negative breast cancer evolution

This study explores the evolution of tumor and blood immune microenvironment and related mechanisms that shape breast cancer progression.

Request Access

IrsiCaixa 2

These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorised Personnel: The individuals at the User Institution to whom IrsiCaixa grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: IrsiCaixa and the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data. External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Institution that has requested access to the Data. Irsicaixa: IrsiCaixa AIDS Research Institute is an international leader in HIV/AIDS research and a landmark in the study of emerging infectious diseases, microbiome and cancer. Contact details: Ctra del Canyet s/n, 08916, Badalona, Spain 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify IrsiCaixa within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify IrsiCaixa prior to any significant changes to the protocol for the Project. 14. The User Institution will notify IrsiCaixa as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. IrsiCaixa may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than IrsiCaixa. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of Spain and Catalonia and shall be subject to the exclusive jurisdiction of the Spanish courts. APPENDIX I – DATASET DETAILS (to be completed by the data producer before passing to applicant) Dataset reference (EGA Study ID and Dataset Details) EGA study ID: EGAC50000000074 Dataset Details (EGAD50000000117): Genomic analyses (WES, RNAseq, ssRNAseq and ssTCRseq) of triple negative breast cancer specimens (tumor and blood). This study explores the evolution of tumor and blood immune microenvironment and related mechanisms that shape breast cancer progression. Name of project that created the dataset Converging and evolving immuno-genomic routes towards immune escape in breast cancer Names of other data producers/collaborators Leticia De Mattos-Arruda, IrsiCaixa Foundation Nuria de la Iglesia, IrsiCaixa Foundation Specific limitations on areas of research Biomedical research in the context of the consent process. Minimum protection measures required - File access: Data can be held in unencrypted files on an institutional compute system, with Unix user group read/write access for one or more appropriate groups but not Unix world read/write access behind a secure firewall. Laptops holding these data should have password protected logins and screenlocks (set to lock after 5 min of inactivity). If held on USB keys or other portable hard drives, the data must be encrypted. APPENDIX II – PROJECT DETAILS (to be completed by the Requestor) Details of dataset requested i.e., EGA Study and Dataset Accession Number Title of the project (in less than 30 words) Brief abstract of the Project in which the Data will be used (500 words max) Brief description of the infrastructure and experience for handling potentially identifiable genetic data securely All Individuals who the User Institution to be named as registered users Name of Registered User Affiliation Email Job Title Supervisor* * PhD student applicants must include their supervisors as a co-applicant and provide their full contact details. All Individuals that should have an account created at the EGA Name of Registered User Email Job Title APPENDIX III – PUBLICATION POLICY IrsiCaixa intend to publish the results of their analysis of this dataset and do not consider its deposition into public databases to be the equivalent of such publications. IrsiCaixa anticipate that the dataset could be useful to other qualified researchers for a variety of purposes. However, some areas of work are subject to a publication moratorium. The publication moratorium covers any publications (including oral communications) that describe the use of the dataset. For research papers, submission for publication should not occur until 12 months after these data were first made available on the relevant hosting database, unless IrsiCaixa has provided written consent to earlier submission. Any use of Data must be acknowledged using the following wording: "This study makes use of data generated by the study entitled “Converging and evolving immuno-genomic routes towards immune escape in breast cancer”, and cite the relevant primary publication (Blanco et al., Nature Communications 2024, PubMed ID 38383522), which is the source of the Data.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001004956 Cancer Genomics
  • Updated list of runs
  • Updated list of runs
  • change release date
  • update of dataset description
  • Dataset Released

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00004977416 fastq.gz 3.1 GB
EGAF00004977417 fastq.gz 7.6 GB
EGAF00004977418 fastq.gz 312.1 MB
EGAF00004977419 fastq.gz 578.2 MB
EGAF00004977420 fastq.gz 3.1 GB
EGAF00004977421 fastq.gz 7.5 GB
EGAF00004977422 fastq.gz 318.1 MB
EGAF00004977423 fastq.gz 584.5 MB
EGAF00005069563 bam 14.6 GB
EGAF00005069564 bam 12.3 GB
EGAF00005069565 bam 12.4 GB
EGAF00005069566 bam 12.7 GB
EGAF00005069567 bam 12.7 GB
EGAF00005069568 bam 13.6 GB
EGAF00005069569 bam 12.8 GB
EGAF00005069570 bam 14.2 GB
EGAF00005069571 bam 16.4 GB
EGAF00005069572 bam 14.9 GB
EGAF00005069573 bam 16.3 GB
EGAF00005069574 bam 14.0 GB
EGAF00005069575 bam 14.4 GB
EGAF00005069576 bam 20.1 GB
EGAF00005069577 bam 19.3 GB
EGAF00005069578 bam 21.8 GB
EGAF00005069579 bam 17.8 GB
EGAF00005069580 bam 17.3 GB
EGAF00005069581 bam 15.4 GB
EGAF00005069582 bam 12.5 GB
EGAF00005069583 bam 14.8 GB
EGAF00005069584 bam 4.4 GB
EGAF00005069585 fastq.gz 10.7 GB
EGAF00005069586 fastq.gz 11.1 GB
EGAF00005069587 fastq.gz 10.2 GB
EGAF00005069588 fastq.gz 10.5 GB
EGAF00005069589 fastq.gz 9.7 GB
EGAF00005069590 fastq.gz 10.0 GB
EGAF00005069591 fastq.gz 10.7 GB
EGAF00005069592 fastq.gz 11.2 GB
EGAF00005069593 fastq.gz 10.0 GB
EGAF00005069594 fastq.gz 10.3 GB
EGAF00005069595 fastq.gz 9.7 GB
EGAF00005069596 fastq.gz 10.1 GB
EGAF00005069597 fastq.gz 9.7 GB
EGAF00005069598 fastq.gz 10.0 GB
EGAF00005069599 fastq.gz 11.8 GB
EGAF00005069600 fastq.gz 12.1 GB
EGAF00005069601 fastq.gz 9.7 GB
EGAF00005069602 fastq.gz 9.9 GB
EGAF00005069603 fastq.gz 11.3 GB
EGAF00005069604 fastq.gz 11.7 GB
EGAF00005069605 fastq.gz 8.9 GB
EGAF00005069606 fastq.gz 9.3 GB
EGAF00005069607 fastq.gz 7.6 GB
EGAF00005069608 fastq.gz 7.9 GB
EGAF00005069609 fastq.gz 8.8 GB
EGAF00005069610 fastq.gz 9.2 GB
EGAF00005069611 fastq.gz 8.1 GB
EGAF00005069612 fastq.gz 8.4 GB
EGAF00005069613 fastq.gz 11.0 GB
EGAF00005069614 fastq.gz 11.6 GB
EGAF00005069615 fastq.gz 8.4 GB
EGAF00005069616 fastq.gz 8.9 GB
EGAF00005069617 fastq.gz 9.1 GB
EGAF00005069618 fastq.gz 9.5 GB
EGAF00005069619 fastq.gz 8.3 GB
EGAF00005069620 fastq.gz 8.6 GB
EGAF00005189118 fastq.gz 5.9 GB
67 Files (707.6 GB)